Even without counting lost productivity, the vaccine effort saved more than it cost.
Five years after the first needles entered arms, a University of Michigan study has quietly settled one of public health's most contested questions: the United States' early and aggressive investment in COVID-19 vaccines returned more than it cost within a single year. The finding is not merely a ledger entry — it is a confirmation that collective action, even imperfect and uncertain, can bend the arc of human suffering toward something more bearable. And yet the virus persists, the uptake falters, and the question of whether society will keep choosing prevention over aftermath remains stubbornly open.
- Hundreds of Americans are still dying from COVID-19 every week in 2025, even as the tools to prevent severe illness exist and are updated annually.
- A rigorous economic model now confirms the federal vaccine program paid for itself within twelve months — a rare moment of clarity in a debate long clouded by politics and fear.
- The study's conservative methodology deliberately left out caregiver losses, out-of-pocket costs, and decades of foundational research funding, meaning the true savings are almost certainly larger than reported.
- Only about 30 percent of the highest-risk seniors have received the updated vaccine, exposing a dangerous gap between what science recommends and what the public is willing to do.
- Researchers are already modeling future vaccine waves in partnership with the CDC, but that work hinges on continued funding and data access — both of which are uncertain.
Five years into the pandemic, the United States made a calculated bet: accelerate vaccine development, purchase doses in bulk, and distribute them free of charge. Sixty-six million adults received at least one dose within the first year. Now, a University of Michigan study published in the journal Vaccine confirms the gamble paid off — the national vaccine effort returned more than it cost within twelve months.
The researchers modeled the full economic picture: vaccine costs, testing, treatment, rare side effects, lost workdays, and deaths. For adults over 40, the program saved more than it spent on medical costs alone. For younger adults aged 18 to 39, direct medical savings fell slightly short, but productivity gains from fewer sick days pushed the effort well past the threshold for cost-effectiveness by national standards.
Lead author Lisa Prosser was careful to note what the model left out — caregiver time, patients' out-of-pocket expenses, and the decades of federally funded basic research that made mRNA vaccines possible. The actual savings, she suggested, are likely considerably larger than reported. Her co-author David Hutton helped build the model from dozens of existing pandemic studies, incorporating long COVID and the full spectrum of illness severity and care costs.
COVID-19 has not faded quietly. Between 575 and 1,000 Americans died from the virus each week in early 2025, and roughly one percent of emergency department visits were COVID-related. The CDC recommends updated annual vaccines for everyone over six months old, with a second dose advised for those 65 and older or immunocompromised.
Despite this, only about 30 percent of seniors — the group most vulnerable to severe illness — have received the updated shot. Prosser and her team are already working with the CDC to model the cost-effectiveness of more recent vaccine campaigns, with projections for fall 2025 rollouts in development. Whether vaccination remains a sound investment will need answering again and again, even as the evidence keeps pointing in the same direction.
Five years into the pandemic, as the first volunteers were rolling up their sleeves for COVID-19 vaccine trials, the United States was making a bet. Within a year, 66 million American adults had received at least one dose—free of charge. Now, a study from University of Michigan researchers confirms what policymakers hoped: that gamble paid off.
The analysis, published in the journal Vaccine, shows the national vaccine effort returned more money than it cost within just twelve months. The researchers accounted for everything: the price of the vaccines themselves, testing and treatment, the rare side effects some people experienced, and the economic weight of lost workdays when someone fell ill or died. Even narrowing the lens to medical costs alone, the program saved more than it spent for adults over 40. For younger adults aged 18 to 39—who face lower risk of severe COVID illness—the vaccination effort cost slightly more in direct medical expenses, but when you factor in the productivity gains from fewer people getting sick, it still cleared the bar for cost-effectiveness by national standards.
Lisa Prosser, the study's lead author and a professor at Michigan's Medical School and School of Public Health, emphasized the conservative nature of the analysis. The model deliberately excluded several categories of savings: the lost wages of people who took time off work to care for sick family members, out-of-pocket costs patients paid for treatment or transportation, and the decades of federally funded basic research that made the mRNA vaccines possible in the first place. "From a broader societal economic perspective and from the perspective of medical care costs, the federal government's decision to accelerate vaccine testing, buy large quantities of vaccine, and support the cost of vaccination in many settings was wise," Prosser said. The actual savings, she suggested, are likely considerably larger than the study reports.
The research team, working with David Hutton, a professor at the School of Public Health and College of Engineering, built their model on findings from dozens of other studies examining different aspects of the pandemic. They included long COVID—the persistent symptoms some people experience after infection—and modeled everything from the likelihood of developing various levels of illness to the typical cost of care at each severity level. The precision of the work reflects how thoroughly the pandemic has been studied, and how much data now exists to answer the question: was it worth it?
Five years later, COVID-19 has not disappeared. Between 575 and 1,000 Americans died from the virus every week in early 2025, according to the most recent complete data. About one percent of emergency department visits in recent months have been for COVID-19. The CDC recommends that everyone over six months old receive at least one dose of the updated vaccines that became available in September 2023 and are now updated annually. For people 65 and older or those with compromised immune systems, a second dose six months after the first is advised.
Yet uptake remains modest. About 30 million people have received the updated vaccine—roughly 30 percent of adults 65 and older, the group at highest risk of severe illness. Prosser and her colleagues have already begun modeling the cost-effectiveness of vaccination waves that occurred after 2021, working with the CDC. They hope to develop projections for the updated vaccines expected to roll out in fall 2025, though that work depends on continued CDC funding and access to real-world data. The question of whether vaccination remains a sound investment, it seems, will need answering again and again.
Notable Quotes
From a broader societal economic perspective and from the perspective of medical care costs, the federal government's decision to accelerate vaccine testing, buy large quantities of vaccine, and support the cost of vaccination in many settings was wise.— Lisa Prosser, lead author of the study and professor at University of Michigan
The Hearth Conversation Another angle on the story
When you say the vaccine investment paid for itself in one year, what does that actually mean in dollars?
It means the medical costs prevented—hospitalizations avoided, deaths prevented, treatment for long COVID that didn't happen—exceeded what the government spent on testing, manufacturing, and distributing the vaccines. For older adults, it was a clear win even before counting lost wages. For younger people, the direct medical savings were close, but once you add in the productivity gains from fewer sick days, it crossed into net positive.
Why does the study exclude things like caregiver time and out-of-pocket costs? Doesn't that make the numbers look better than reality?
It does make them look better, yes—but that's the point. The researchers were being deliberately conservative. They wanted to show the savings using the most defensible, narrowest possible frame. If you included all those other costs—the neighbor who stayed home to watch a sick friend's kids, the person who paid for their own test—the actual savings would be even larger.
So the real economic benefit was bigger than what they're reporting?
Almost certainly. They didn't count the decades of basic research the government funded that made mRNA vaccines possible in the first place. They didn't count caregiver burden. They didn't count what people paid out of pocket. The study is essentially saying: even if we ignore all that, the investment still paid for itself.
But people are still dying. Over 500 a week. Does that change the economic calculation?
No, it changes the moral one. The economics show the investment was rational and saved money. But 500 to 1,000 deaths a week means the vaccination effort, however cost-effective, hasn't solved the problem. It's reduced it. And right now, only 30 percent of the highest-risk people are getting the updated vaccines. That's a separate question from whether the original investment was wise—it's about what we do now.
What happens next with this research?
They want to model the updated vaccines rolling out this fall, but it depends on CDC funding. The researchers have already looked at vaccination waves after 2021. The idea is to keep answering the same question: is this still worth doing? The answer so far has been yes. But you need current data to know if that remains true.